有图像解读标准来规范报告前列腺特异性膜抗原（PSMA）靶向正电子发射断层扫描（PET）。由于高达10%的前列腺癌（PC）不表达PSMA，因此还评估了其他目标，如胃泌素释放肽受体（GRPR）。关于GRPR靶向成像的研究在前列腺癌的分期和生化复发中的使用逐渐增加。因此，我们提出了一种修改版的前列腺癌分子成像标准化评估（PROMISE）标准（mPROMISE）用于GRPR靶向PET。回顾了最初在我们机构进行的前瞻性研究中的[68Ga]Ga-RM2 PET数据：44名患者进行分期成像，100名患者进行生化复发PC成像。两位核医学专家根据mPROMISE标准独立评估了PET。第三位专家读者作为标准参考。计算了GRPR表达、前列腺床（T）、淋巴结（N）、骨骼（Mb）转移、器官（Mc）转移和扫描的最终判断的互评可靠性。在分期时，GRPR PET的评估者间可靠性为GRPR表达适度（0.59；95%置信区间[CI] 0.40, 0.78），T分期大致完全（0.78；95% CI 0.63, 0.94），N分期几乎完全（0.97；95% CI 0.92, 1.00）和最终判断几乎完全（0.92；95% CI 0.82, 1.00）。在生化复发时，GRPR表达的评读者间协议为大致完全（0.70；95% CI 0.59, 0.81），最终判断为大致完全（0.65；95% CI 0.53, 0.78），而在主要类别（T、N、Mb、Mc）中几乎完全完全一致。与标准参考相比，mPROMISE标准在所有子集中表现出可接受的性能。使用mPROMISE标准解读GRPR靶向PET显示了其在所有主要类别上的可靠性，评分者间达到了大致完全或几乎完全一致。所提出的PROMISE标准的修改将有助于临床医生降低不确定性水平，以及实现GRPR靶向PET的统一评估、报告和可比性的临床试验。Clinicaltrials.gov识别号：NCT03113617和NCT02624518。© 2023. 作者，Springer-Verlag GmbH Germany独家许可，Springer Nature的一部分。

There are image interpretation criteria to standardize reporting prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET). As up to 10% of prostate cancer (PC) do not express PSMA, other targets such as gastrin-releasing peptide receptor (GRPR) are evaluated. Research on GRPR-targeted imaging has been slowly increasing in usage at staging and biochemical recurrence (BCR) of PC. We therefore propose a modification of the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria (mPROMISE) for GRPR-targeted PET.[68 Ga]Ga-RM2 PET data from initially prospective studies performed at our institution were retrospectively reviewed: 44 patients were imaged for staging and 100 patients for BCR PC. Two nuclear medicine physicians independently evaluated PET according to the mPROMISE criteria. A third expert reader served as standard reference. Interreader reliability was computed for GRPR expression, prostate bed (T), lymph node (N), skeleton (Mb), organ (Mc) metastases, and final judgment of the scan.The interrater reliability for GRPR PET at staging was moderate for GRPR expression (0.59; 95% confidence interval [CI] 0.40, 0.78), substantial for T-stage (0.78; 95% CI 0.63, 0.94), and almost perfect for N-stage (0.97; 95% CI 0.92, 1.00) and final judgment (0.92; 95% CI 0.82, 1.00). The interreader agreement at BCR showed substantial agreement for GRPR expression (0.70; 95% CI 0.59, 0.81) and final judgment (0.65; 95% CI 0.53, 0.78), while almost perfect agreement was seen across the major categories (T, N, Mb, Mc). Acceptable performance of the mPROMISE criteria was found for all subsets when compared to the standard reference.Interpreting GRPR-targeted PET using the mPROMISE criteria showed its reliability with substantial or almost perfect interrater agreement across all major categories. The proposed modification of the PROMISE criteria will aid clinicians in decreasing the level of uncertainty, and clinical trials to achieve uniform evaluation, reporting, and comparability of GRPR-targeted PET.Clinicaltrials.gov Identifier: NCT03113617 and NCT02624518.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.